Join our C₂N Diagnostics team at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) October 24 – 27 in Boston
Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology, Director of the Tracy Family SILQ Center and Bateman Lab for Neurodegenerative Biology, the Dominantly Inherited Alzheimer Network (DIAN), the Knight Family DIAN Trials Unit (DIAN-TU), Washington University, and C2N Scientific Co-Founder, will receive the 2023 CTAD Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research in recognition of his pioneering work in Alzheimer’s disease research and plasma biomarkers in AD diagnosis.
Plenary and Late Breaking Oral Sessions and Posters
Multiple conference presentations and posters will offer exciting new insights relating to C₂N’s PrecivityAD2™ and PrecivityAD® blood tests, and other unique biomarkers. Clinical and analytical data will be shared in ten session presentations and three scientific posters outlined below.
On October 25th, C₂N Vice President Dr. Tim West, will share clinical validation data for the PrecivityAD2™ test and Dr. Mark Monane, C₂N Medical Officer, will share the economic utility of blood biomarkers in Alzheimer’s diagnoses.
The full schedule of sessions and posters that include work with C₂N collaborators is listed below.
To schedule a meeting with the C₂N team in Boston, please send us an email: research@c2n.com.
Tuesday, October 24
4:00 p.m.
Welcome ceremony and CTAD Lifetime Achievement Award Alzheimer’s Disease Therapeutic Research
Presented to Randall J. Bateman, MD, in recognition for his pioneering work in Alzheimer’s Disease Research and Plasma Biomarkers in AD diagnostics. Introduction by Reisa Sperling, President of the CTAD23 Scientific Committee and the CTAD Organizing Committee
4:30 p.m.
KEYNOTE 1 – Pathophysiology insights of blood tests, disease modifying treatments, and the potential for prevention of Alzheimer’s disease
Randall J. Bateman, Washington University School of Medicine, St. Louis, MO (United States)
4:55 p.m.
SYMPOSIUM 1 – The Effects of Race and Gender on Amyloid Positivity
Chair: Suzanne Schindler, Washington University, St. Louis, MO (United States)
Introduction: Determining amyloid status in different racial, ethnic, and gender groups
5:35 p.m.
LB1 – Baseline Levels and Longitudinal changes in plasma AΒ42/40 among self-identified black and white individuals
Chengjie Xiong, Washington University - St. Louis, MO (United States)
6:05 p.m.
LB3 – Topline Results from the Phase 2 PIONEER Trial of Oral T3D-959 for the Treatment of Patients Diagnosed with Mild-to-Moderate Alzheimer’s Disease
John Didsbury, T3D Therapeutics, Inc. - Research Triangle Park (United States)
Wednesday, October 25
8:45 a.m.
LB7 – PrecivityAD2 blood test: An analytically and clinically validated test combining p-tau217/np-tau217 and Aβ42/40 ratios to identify brain amyloid
Tim West, C₂N Diagnostics - St. Louis (United States)
11:35 a.m.
OC2 – Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer’s disease
Gemma Salvadó, Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University - Lund (Sweden)
2:35 p.m.
OC7 – Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Patients with Signs and Symptoms of Cognitive Impairment
Mark Monane, C₂N Diagnostics - St Louis (United States)
Thursday, October 26
5:05 p.m.
LATE BREAKING SYMPOSIUM 6
Implementation blood biomarkers in clinical practice and trials
Chair: Stephen Salloway, Brown University - Providence (United States)
Presentation 2: A highly accurate blood test for Alzheimer’s disease pathology has performance equivalent or superior to clinically used cerebrospinal fluid tests
Oskar Hansson, Lund University – Lund (Sweden)
Presentation 3: Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's Disease
Robert Rissman, University California San Diego – San Diego (United States)
Friday, October 27
4:15 p.m.
LB26 – Feasibility of remote blood collection and plasma biomarker analyses to assess eligibility for Alzheimer’s disease preclinical clinical trials - The AlzMatch Study
Rema Raman, Alzheimer’s Therapeutic Research Institute, University of Southern California - San Diego (United States)
Other presentations with C₂N biomarker data expected to be shared from industry collaborators throughout the CTAD conference.
Conference Posters:
P094 Plasma biomarkers and longitudinal cognitive decline in non-demented Alzheimer’s disease
Karly Cody, Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin - Madison (United States)
P096 Bio-Hermes study topline results: Aß 42/40 and p-Tau 181/217 blood-based biomarkers compared to amyloid PET and CSF in a diverse, community-based population
Douglas Beauregard, Global Alzheimer’s Platform Foundation - Washington, DC (United States)
LP121 memTEST, a direct-to-consumer self-administered digital cognitive test SELF completed in under 10 minutes on mobile (Android or iPhone), PC, or tablet to increase clinical trial participation and decrease screen fails for verbal screening tests and fluid biomarkers in Alzheimer’s Disease clinical trials
David Watson, K2 Medical Research - Maitland (United States)
The full 2023 CTAD Conference Program is available at:
https://www.ctad-alzheimer.com/program-0
Contact research@c2n.com to schedule a meeting with us.
We look forward to seeing you in Boston!
About C₂N Diagnostics, LLC
C₂N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation™. C₂N strives to provide exceptional laboratory services and products in the field of brain health. C₂N’s biomarker services and products are used for: clinical decision making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. For more information visit www.C2N.com.